ABUS Arbutus Biopharma Corporation Loading...

From MRNA earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:00
May 01 ◎
Jamie Mock CFO, Moderna, Inc. MRNA Q1 FY26 call
A $950M settlement payment to Arbutus/Genebon is due in Q3 2026, but Moderna has not reserved the potential $1.3B Section 1498 liability, creating a binary cash risk event in 2027-2028. — A negative ruling would be a significant cash drain on an already cash-burning company.
ABUS
HIGH

About ABUS Analyst Coverage

Buzzberg tracks ABUS (Arbutus Biopharma Corporation) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Jamie Mock.